View Post

Optiscan Imaging (ASX:OIL) begins stage three of breast cancer study

In Clinical Trials by Barbara Jacoby

By: Julia Seymour From: themarketherald.com Optiscan Imaging (OIL) has begun stage three of its breast cancer study in Melbourne. The study will involve 20 breast cancer patients at Royal Melbourne Hospital, Frances Perry House and Epworth Hospital using Optiscan’s FIVE2/Viewnvivo endomicroscope. The Optiscan endomicroscope enables real-time, 3D, ‘in vivo’ imaging of human tissue at the cellular level, providing instant virtual …

View Post

Novel hybrid device to boost research on metastatic process of breast cancer cells

In Clinical Trials by Barbara Jacoby

Source: FETFX From: news-medical.net European researchers are working on a novel hybrid device to better understand the metastatic process of cancer cells traveling from breast to bone and fast screen new drugs against it. The spread of cancer cells to other parts of the body, known as metastasis, is the main cause of cancer-related deaths. According to the US National …

View Post

Examining resistance to breast cancer treatments

In Clinical Trials by Barbara Jacoby

By: Molly Chiu From: bcm.edu The combination of CDK4/6 inhibitors with endocrine therapy is the standard of care for patients with estrogen receptor-positive (ER+) and HER2-negative (ER+/HER2-) metastatic breast cancer. However, a subset of patients will have tumors with intrinsic resistance to this therapy and most patients will develop resistant disease at some point during treatment. Researchers at the Lester …

View Post

Sanford opens I-SPY 2 clinical trial for breast cancer

In Clinical Trials by Barbara Jacoby

From: sanfordhealth.org Sanford Health has a new option for patients diagnosed with breast cancer. The I-SPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And molecular anaLysis 2), is an adaptive platform clinical trial, created to identify successful treatments for Stage II/III breast cancer while minimizing the number of required participants and time required to …

View Post

Trial Explores Preoperative Window for Amcenestrant Therapy in Early Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Denise Myshko From: onclive.com Investigators are seeking to determine whether amcenestrant (SAR439859), an investigational oral endocrine therapy, can generate meaningful antitumor activity when administered as short-term preoperative therapy to postmenopausal patients with newly diagnosed early breast cancer. The phase 2 AMEERA-4 trial (NCT04191382) is testing 2 dose levels of amcenestrant versus letrozole given for 14 days to patients with …

View Post

PET Imaging Reveals Which Breast Cancer Patients Won’t Respond to Hormone Therapy

In Clinical Trials by Barbara Jacoby

By: Whitney J. Palmer From: diagnosticimaging.com Hormone therapy is only effective in roughly half of estrogen receptor-positive cancers. Being able to identify patients that will not respond could save valuable treatment time. The answer to whether hormone replacement therapy will work for a woman with breast cancer likely comes down to whether her estrogen receptors are working – a function …

View Post

SORLA protein promotes the growth of breast cancer brain metastasis

In Clinical Trials by Barbara Jacoby

Source: University of Turku From: news-medical.net SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells. Professor Johanna Ivaska’s research group at Turku Bioscience observed that SORLA functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor HER3 counteracts HER2 targeting therapy in HER2-positive cancers. …

View Post

Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Ayala Pharmaceuticals From: globenewswire.com Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the first patient dosed in the Phase 2 TENACITY clinical trial of its potent, selective small molecule AL101, for the treatment of patients with Notch-activated recurrent or metastatic …

View Post

Celcuity Announces Breast Cancer Clinical Trial Collaboration with Sarah Cannon and Pfizer to Study New Drug Regimen

In Clinical Trials by Barbara Jacoby

From: businesswire.com – Trial will evaluate the efficacy and safety of Pfizer’s targeted therapies, VIZIMPRO® and XALKORI®, in patients with metastatic HER2-negative breast cancer selected by Celcuity’s CELsignia Multi-Pathway Activity Test – First clinical trial to treat patients diagnosed with hyperactive HER2 and c-Met signaling breast cancers with matching targeted therapies Celcuity Inc. (Nasdaq: CELC), a clinical stage biotechnology company …

View Post

IU researchers identify how breast cancer cells evade immune attacks

In Clinical Trials by Barbara Jacoby

Source: Indiana University School of Medicine From: news-medical.net Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified how breast cancer cells hide from immune cells to stay alive. The discovery could lead to better immunotherapy treatment for patients. Xinna Zhang, PhD, and colleagues found that when breast cancer cells have an increased level of a …